Inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations

Blood

Volumn 121, Issue 2, 2013, Pages 385-391

  Schwind, Sebastian ^a   Edwards, Colin G ^a   Nicolet, Deedra ^a,b   Mrózek, Krzysztof ^a   Maharry, Kati ^a,b   Wu, Yue Zhong ^a   Paschka, Peter ^a   Eisfeld, Ann Kathrin ^a   Hoellerbauer, Pia ^a   Becker, Heiko ^a   Metzeler, Klaus H ^a   Curfman, John ^a   Kohlschmidt, Jessica ^a,b   Prior, Thomas W ^c   Kolitz, Jonathan E ^d   Blum, William ^a   Pettenati, Mark J ^e   Cin, Paola Dal ^f   Carroll, Andrew J ^g   Caligiuri, Michael A ^a   Larson, Richard A ^h   Volinia, Stefano ^a   Marcucci, Guido ^a   Bloomfield, Clara D ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e WAKE FOREST BAPTIST HEALTH   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CASPASE; CORE BINDING FACTOR BETA PROTEIN; CYTARABINE; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 11; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CHROMOSOME 8; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION PROFILING; GENE FUSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LEUKEMIA CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; PRIORITY JOURNAL; TRISOMY; UPREGULATION;

EID: 84872335622     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-07-442772     Document Type: Article

References (39)

1. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
2. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115-136.
3. Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100(13):4325-4336.
4. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58(18):4173-4179. (Pubitemid 28440576)
5. Byrd JC, Ruppert AS, Mrózek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22(6):1087-1094. (Pubitemid 41095042)
6. Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102(2):462-469. (Pubitemid 36841961)
7. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741-3750. (Pubitemid 41102131)
8. Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23(24):5705-5717.
9. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135(2):165-173. (Pubitemid 44401613)
10. Mrózek K, Marcucci G, Paschka P, Bloomfield CD. Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol. 2008;20(6):711-718.
11. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. 2006;24(24):3904-3911. (Pubitemid 46630738)
12. Care RS, Valk PJM, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. 2003;121(5):775-777. (Pubitemid 36718195)
13. Liu P, Tarlé SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261(5124):1041-1044.
14. Claxton DF, Liu P, Hsu HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood. 1994;83(7):1750-1756. (Pubitemid 24107896)
15. Park TS, Lee ST, Song J, et al. Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits. Cancer Genet Cytogenet. 2009;189(2):87-92.
16. Liu PP, Wijmenga C, Hajra A, et al. Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells. Genes Chromosomes Cancer. 1996;16(2):77-87.
17. van Dongen JJM, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(12):1901-1928.
18. Schnittger S, Bacher U, Haferlach C, Kern W, Haferlach T. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients. Leukemia. 2007;21(4):725-731. (Pubitemid 46444556)
19. Shurtleff SA, Meyers S, Hiebert SW, et al. Heterogeneity in CBFβ/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16; 16)(p13;q22) in acute myelogenous leukemia. Blood. 1995;85(12):3695-3703.
20. van der Reijden BA, Lombardo M, Dauwerse HG, et al. RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts. Blood. 1995;86(1):277-282.
21. Mrózek K, Carroll AJ, Maharry K, et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol. 2008;33(2):239-244.
22. Mrózek K, Prior TW, Edwards C, et al. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2001;19(9):2482-2492.
23. Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene- and microRNA-expression signatures. J Clin Oncol. 2012;30(25):3109-3108.
24. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742-750.
25. Maere S, Heymans K, Kuiper M. BiNGO: a cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics. 2005;21(16):3448-3449. (Pubitemid 41222459)
26. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
27. Westfall PH, Tobias RD, Rom D, et al. Multiple comparisons and multiple tests using the SAS system. Cary, NC: SAS Institute; 1999.
28. Lück SC, Russ AC, Du J, et al. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol. 2010;148(6):925-937.
29. Vassen L, Khandanpour C, Ebeling P, et al. Growth factor independent 1b (Gfi1b) and a new splice variant of Gfi1b are highly expressed in patients with acute and chronic leukemia. Int J Hematol. 2009;89(4):422-430.
30. Khandanpour C, Thiede C, Valk PJM, et al. A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. Blood. 2010;115(12):2462-2472.
31. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97(5):1172-1179. Amutation of human cytochrom (Pubitemid 32183737)
32. Morison IM, Cramer Bordé EM, Cheesman EJ, et al. Amutation of human cytochrome C enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet. 2008;40(4):387-389.
33. Cramer Bordé E, Ouzegdouh Y, Ledgerwood EC, Morison IM. Congenital thrombocytopenia and cytochrome C mutation: a matter of birth and death. Semin Thromb Hemost. 2011;37(6):664-672.
34. Anzai N, Lee Y, Youn B-S, et al. c-kit associated with the transmembrane 4 superfamily proteins constitutes a functionally distinct subunit in human hematopoietic progenitors. Blood. 2002;99(12):4413-4421. (Pubitemid 34627209)
35. Tibes R, Keating MJ, Ferrajoli A et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106(12):2645-2651.
36. Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol. 2011;154(2):161-174.
37. DiMartino JF, Lacayo NJ, Varadi M, et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia. 2006;20(3):426-432. (Pubitemid 43291739)
38. Zhao L, Melenhorst JJ, Alemu L, et al. KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. Blood. 2012;119(6):1511-1521.
39. Edwards CG, Maharry K, Mrózek K, et al. Cytogenetic, molecular and clinical features associated with rare CBFB-MYH11 fusion transcripts in patients (pts) with acute myeloid leukemia (AML) and inv(16)/t(16;16) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1077. Abstract 2514.